Exelixis, Ryvu Therapeutics to develop new targeted cancer therapies
Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies using Ryvu’s STING technology
Page 9 - Peter Lamb News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Lamb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Lamb Today - Breaking & Trending Today
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-
– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential –ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and...
Source: pharmiweb.com
Exelixis, Inc.: Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which
Source: finanznachrichten.de
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
ALAMEDA, Calif. & LUND, Sweden--(BUSINESS WIRE)--Jun 16, 2022--
Source: cadillacnews.com
Exelixis, Inc.: Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening
Source: finanznachrichten.de